Toggle light / dark theme

Feb. 1, 2024 – A common condition called polycystic ovary syndrome that causes irregular menstrual cycles has been linked to signs of early cognitive decline.

Known as PCOS, the condition may affect more than 1 in 10 women, and is among the most common causes of infertility. In addition to ovulation problems, PCOS can cause excess hair growth on the face and the other parts of the body, as well as abnormal growths on the ovaries. Women with PCOS are at a particularly heightened risk of getting type 2 diabetes, as well as other serious health conditions like heart disease, high blood pressure, cholesterol problems, and sleep apnea, particularly if the women are overweight.

This latest study looked for possible links between PCOS and brain health in women once they were in their late 40s or older.

Researchers at Aalto University were looking for better ways to instruct dance choreography in virtual reality. The new WAVE technique they developed will be presented in May at the CHI conference for human-computer interaction research.

Previous techniques have largely relied on pre-rehearsal and simplification.

“In , it is difficult to visualize and communicate how a dancer should move. The is so multi-dimensional, and it is difficult to take in rich data in ,” says Professor Perttu Hämäläinen.

The following is a summary of “Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways,” published in the April 2024 issue of Hematology by Wang et al.

The intricate interplay between programmed cell death ligand 1 (PD-L1), expressed on the surface of tumor cells, and programmed cell death 1 (PD-1), expressed on T cells, constitutes a pivotal mechanism fostering immune evasion by tumor cells through the thwarting of effective tumor antigen-specific T cell activation. The advent of PD-1/PD-L1 blockade has emerged as a transformative strategy in combating tumor immune evasion, garnering substantial interest within the oncology landscape. Clinical investigations have underscored the remarkable efficacy and safety profile of PD-1/PD-L1 blocking antibodies across a spectrum of malignancies, offering a beacon of hope for patients.

Nonetheless, the therapeutic landscape of anti-PD-1/PD-L1 interventions is fraught with challenges, including limited indications and the emergence of drug resistance, necessitating a nuanced approach to therapeutic intervention. Accordingly, unraveling additional regulatory pathways and molecular players associated with PD-1/PD-L1 signaling assumes paramount importance, alongside the strategic implementation of combinational therapeutic modalities, to address the multifaceted dynamics of tumor immune evasion.